Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The portable, low-resource MiniDock MTB test, evaluated across multiple countries, shows promise for detecting pulmonary tuberculosis using sputum and tongue swabs.
In a prospective cohort of 166 participants (and in a 63-participant validation cohort), dermal α-synuclein and 4-repeat tau seed amplification, combined with serum neurofilament light chain assays, were able to identify parkinsonian syndromes.
An open-label, randomized controlled phase 2 trial comparing favipiravir with ribavirin for the treatment of mild-to-moderate Lassa fever in Nigeria found that favipiravir was safe and well tolerated and supports its further optimization as a treatment alternative.
Part of the Hong Kong Genome Project, genomic analyses of more than 20,000 participants provide information on clinically relevant variants for the Chinese population and offer insights on the implementation of genomic medicine initiatives.
Improvements in the Articulate Medical Intelligence Explorer, a large language model designed for diagnostic dialogue, enable the model to request, interpret and reason about multimodal medical data.
The proposed clinical features of traumatic encephalopathy syndrome have low predictive value for chronic traumatic encephalopathy pathology, raising significant concern for incorrect diagnoses of neurodegeneration in former athletes.
Subcutaneous injections of abatacept were superior to oral hydroxychloroquine in preventing progression to persistent arthritis in individuals with palindromic rheumatism.
This 2026 update integrates emerging trial evidence — particularly for weight loss and liver disease — to refine EASO’s treatment algorithm for obesity management.
In a randomized trial, pasteurized Akkermansia muciniphila improved weight loss maintenance and metabolic health after a low-energy diet, especially in individuals with initially lower Akkermansia levels. The work suggests leveraging gut A. muciniphila as a potential target for weight management.
As presented at the European Congress on Obesity, this randomized, placebo-controlled trial demonstrates that oral orforglipron, a nonpeptide GLP-1 receptor agonist, preserves weight loss and cardiometabolic benefits achieved with injectable GLP-1 receptor agonist therapies, making it a viable oral maintenance strategy.
The BIOMEDE trial, although negative for its primary endpoint, illustrates the utility of adaptive trial designs and biopsy-informed tumor profiling in guiding treatment decisions and patient counseling — and provides mechanistic evidence that can inform future therapeutic strategies.
Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate scientific evidence to support obesity management across global populations.
A phylogenetic analysis examined the origins of the first mpox outbreak in Sierra Leone and found evidence of an emerging lineage (G.1) that has likely descended from the Nigerian epidemic and emerged in Sierra Leone months before first detection.
In a first-in-human trial combining the transplantation of CD33-negative CRISPR-edited hematopoietic cells with the CD33-targeted antibody–drug conjugate gemtuzumab ozogamicin, all transplanted patients achieved primary engraftment, and the treatment was well tolerated.
A first-in-human trial involving selective removal of the placental protein sFlt-1 in preterm pre-eclampsia provides critical safety data, and could mark the beginning of a new era of targeted therapy for this potentially lethal pregnancy complication.
As presented at the 2026 ESC Heart Failure Congress, in a large randomized controlled trial in patients with heart failure with reduced or mildly reduced ejection fraction, treatment with low-dose digoxin was generally safe and well tolerated, but did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality.
As presented at the 2026 ESC Heart Failure Congress, in a phase 2 randomized trial in patients with heart failure with reduced left ventricular ejection fraction after myocardial infarction, treatment with CDR132L, an antisense oligonucleotide inhibitor of miR-132, was well tolerated but did not have a significant effect on measures of left ventricular structure or function.
